C4 Therapeutics Q2 FY26 net loss narrows to $23.6 million; revenue rises to $6.6 million
CCCC•Cash position rises
Cash, cash equivalents and marketable securities rose to $300.4 million, reflecting $33.5 million of ATM proceeds and a $20 million Roche upfront payment.
Q2 revenue and loss improve
C4 Therapeutics posted Q2 revenue of $6.6 million, up 1.54% year over year, helped by revenue recognized under its new Roche DAC collaboration.
Net loss narrowed to $23.6 million; loss per share improved to $0.18.
Clinical timeline remains on track
Phase 2 MOMENTUM enrollment remains on track to finish in Q1 2027. Initial ORR data are expected in 2H 2027, with additional cemsidomide combination updates slated for 2H 2026.
Expenses decline on lower stock-based compensation
Research and development expense fell 6.49% to $24.5 million. General and administrative expense eased to , both on lower stock-based compensation.
